Deutsche Bank Downgrades Novo Nordisk to ‘Sell’: Target Price Slips 9%

Deutsche Bank has turned its stance on Novo Nordisk from ‘Hold’ to ‘Sell’, cutting its target price by 9% to 265 DKK amid concerns over the future of its flagship products Ozempic and Wegovy.

Shift in Outlook: From ‘Hold’ to ‘Sell’

■The downgrade signals doubts about the company's revenue growth and market share prospects.

■The previous $5.25 target price was lowered to $4.83.

■Key drivers include heightened regulatory risks and intensified competition in the prescription‑drug sector.

Is Ozempic’s Revenue Momentum Sustainable?

■Ozempic generated $6.4 billion in 2023.

■Wegovy’s growth has slowed, showing less than a 3% increase.

■The revised target reduces the projected $10 billion annual growth to 7%.

Market Reaction: Rapid and Sharp

■Novo Nordisk shares fell 2.3% at opening.

■Within 30 minutes, the stock experienced a 5% swing.

■Investors are re‑examining dividend and buyback plans.

Strategic Takeaways for Investors

■The dividend yield remains at 3.5%, but sustainability concerns are rising.

■The firm plans a $1.5 billion buyback program through 2024.

■The new outlook projects a 12% decline in share value in a low‑growth environment.

For value‑focused investors, this signals a need to reassess high risk and potential returns. Deutsche Bank’s fresh perspective frames Novo Nordisk’s long‑term growth potential against entrepreneurial and regulatory realities.